Biogen Inc. $BIIB Stake Trimmed by Hillman Capital Management Inc.

Hillman Capital Management Inc. lowered its position in shares of Biogen Inc. (NASDAQ:BIIB) by 20.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 30,516 shares of the biotechnology company’s stock after selling 7,838 shares during the quarter. Biogen accounts for about 3.4% of Hillman Capital Management Inc.’s investment portfolio, making the stock its 7th largest position. Hillman Capital Management Inc.’s holdings in Biogen were worth $5,371,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. Captrust Financial Advisors lifted its holdings in Biogen by 5.1% during the fourth quarter. Captrust Financial Advisors now owns 17,375 shares of the biotechnology company’s stock valued at $3,058,000 after purchasing an additional 843 shares in the last quarter. Fred Alger Management LLC lifted its holdings in Biogen by 39,074.8% during the fourth quarter. Fred Alger Management LLC now owns 798,774 shares of the biotechnology company’s stock valued at $140,576,000 after purchasing an additional 796,735 shares in the last quarter. &PARTNERS lifted its holdings in Biogen by 21.4% during the fourth quarter. &PARTNERS now owns 4,285 shares of the biotechnology company’s stock valued at $833,000 after purchasing an additional 755 shares in the last quarter. Royal Bank of Canada raised its position in shares of Biogen by 8.8% during the fourth quarter. Royal Bank of Canada now owns 541,825 shares of the biotechnology company’s stock valued at $95,356,000 after buying an additional 43,705 shares during the last quarter. Finally, Persistent Asset Partners Ltd bought a new stake in shares of Biogen during the fourth quarter valued at approximately $506,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Analyst Ratings Changes

BIIB has been the topic of several recent analyst reports. JPMorgan Chase & Co. lifted their price objective on shares of Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a research report on Thursday, April 23rd. Barclays initiated coverage on shares of Biogen in a research report on Thursday, February 19th. They set an “equal weight” rating and a $185.00 price objective on the stock. Freedom Capital upgraded shares of Biogen from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 1st. Truist Financial reduced their price objective on shares of Biogen from $193.00 to $189.00 and set a “hold” rating on the stock in a research report on Monday, April 13th. Finally, UBS Group upgraded shares of Biogen from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $185.00 to $225.00 in a research report on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $216.70.

Biogen Trading Down 1.5%

Shares of BIIB opened at $195.61 on Wednesday. The company’s fifty day moving average is $189.52 and its 200 day moving average is $184.58. Biogen Inc. has a fifty-two week low of $121.05 and a fifty-two week high of $205.97. The stock has a market capitalization of $28.88 billion, a PE ratio of 20.99 and a beta of 0.20. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping the consensus estimate of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The company had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter in the previous year, the business posted $3.02 earnings per share. Biogen’s quarterly revenue was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Sell-side analysts expect that Biogen Inc. will post 14.18 earnings per share for the current fiscal year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.